News
Please enjoy the latest industry news aggregated from top Life Sciences sources including BioPharma Dive, FierceBiotech and STAT.
-
Opinion: Oral immunotherapy can be a game changer for many with food allergies
Oral immunotherapy isn't a miracle cure. It can help individuals with peanut allergies successfully consume one peanut. That might not sound like a lot, but it can make a life-changing…... Read more
-
Democrats’ drug pricing bill is a sneak peek at the party’s 2020 campaign message
There’s not much hope for a bipartisan drug pricing compromise in Washington. Instead, Democrats are using their marquee drug bill as a weapon on the 2020 campaign trail... Read more
-
‘Dump it down the drain’: How contaminants from prescription-drug factories pollute waterways
An investigation identified for the first time pharmaceutical companies whose factories are likely dumping substantial quantities of drugs into rivers and streams.... Read more
-
UniQure, Pfizer updates hint at gene therapy potential in hemophilia B
Uniqure and Pfizer are advancing toward market one-time treatments for the blood-clotting disorder, with Takeda about to begin clinical testing of its own therapy. ... Read more
-
Opinion: 11-country survey of primary care physicians shows where U.S. is lagging and keeping pace
A strong emphasis on primary care across our health care system and continued benchmarking of U.S. health care performance against that of other wealthy nations will point us to a…... Read more
-
STAT Plus: In tight Massachusetts job market, it’s relo for biotech and remote for tech hires
So what are fast-growing tech and biotech companies doing to fill open jobs in the waning days of 2019?... Read more
-
STAT Plus: With new trade deal, Trump deals a blow to drug makers
The newly unveiled trade deal doesn't include any protections for high-tech biologic drugs.... Read more
-
Sanofi to restructure its Onduo, Verily partnership alongside diabetes exit
As its new CEO begins to move Sanofi away from new diabetes research, the drugmaker—and producer of one of the world’s top-selling insulins—will also look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.... Read more
-
Under new CEO, Sanofi stops diabetes, heart research and plans $2.2B in cost cutting
"We've been slow. We haven't empowered enough," CEO Paul Hudson said Tuesday in rolling out his strategy for the French pharma.... Read more
-
STAT Plus: GAO finds ongoing problems with FDA inspections of foreign drug facilities
While the FDA had 190 inspectors in the U.S. who conducted most foreign inspections, another 58 positions were vacant.... Read more
-
Is $9.7B too big a price for The Medicines Company? Novartis itself seems to think so
When Novartis unveiled its $9.7 billion buyout of The Medicines Company a few days ago, several industry watchers suggested the price was too high. Turns out, Novartis' own number-crunching "could not justify $85 per share" for the PCSK9 drug developer, SEC documents show—but even so, the company at one point... Read more
-
Why do we need a NASH drug? NASH leaders weigh in
NASH leaders, including Genfit, Intercept Pharmaceuticals, Gilead and NGM Biopharmaceuticals, discuss why we need a drug for the disease and the challenges companies and doctors face in diagnosing and treating patients.... Read more
-
CEO Paul Hudson has sharp words for Sanofi's mistakes—and a pointed plan he thinks will fix them
Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab. The company has long been a leader in diabetes and cardiovascular diseases, but it won't be focused there going forward. Instead, it's focusing on rare... Read more
-
For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans
Christi Shaw, who was named CEO of Kite five months ago, sees opportunities for the cellular therapies in new cancer types and earlier treatment settings.... Read more
-
Leukemia rivals try to stay ahead as Merck, Lilly chase
Merck's surprise buyout of ArQule will heat up competition in a class of cancer drugs that includes AbbVie and J&J's Imbruvica and AstraZeneca's Calquence.... Read more